Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMA401 in postherpetic neuralgia
2011-000977-29Phase 2Completed
- Sponsor
- Spinifex Pharmaceuticals
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing EMA401 with Placebo (2 arms). Primary endpoint: Change in mean pain intensity score. Started Apr 2011; status: completed.
02
Drugs
olodanrigan
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2011-000977-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000977-29.